Dupilumab

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4857 publications

Topical calcineurin inhibitors for atopic dermatitis are not associated with the development of subsequent lymphoma: A pharmacovigilance study using the FAERS database (2014-2025).

Topical calcineurin inhibitors for atopic dermatitis are not associated with the development of subsequent lymphoma: A pharmacovigilance study using the FAERS database (2014-2025).

Journal: JAAD international
Published: April 13, 2026

Letter: Cost-per-Responder Analysis of Tralokinumab Versus Dupilumab for Moderate-to-Severe Atopic Dermatitis Across Universal Health Care Systems.

Letter: Cost-per-Responder Analysis of Tralokinumab Versus Dupilumab for Moderate-to-Severe Atopic Dermatitis Across Universal Health Care Systems.

Journal: Dermatitis : contact, atopic, occupational, drug
Published: April 10, 2026

New and Emerging Drug Reactions.

New and Emerging Drug Reactions.

Journal: Dermatologic clinics
Published: April 08, 2026

Immune checkpoint inhibitor-associated scleroderma refractory to corticosteroids: Clinical improvement with intravenous immune globulin and dupilumab.

Immune checkpoint inhibitor-associated scleroderma refractory to corticosteroids: Clinical improvement with intravenous immune globulin and dupilumab.

Journal: JAAD case reports
Published: April 06, 2026

High Response Rates and Predictors in Patients with CRSwNP Treated With Mepolizumab and Dupilumab: Results From a Prospective, Multicenter Cohort Study.

High Response Rates and Predictors in Patients with CRSwNP Treated With Mepolizumab and Dupilumab: Results From a Prospective, Multicenter Cohort Study.

Journal: American journal of rhinology & allergy
Published: April 06, 2026

Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3-4 randomized trials.

Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3-4 randomized trials.

Journal: The Journal of dermatological treatment
Published: April 01, 2026

The patient journey in prurigo nodularis: what lies ahead.

The patient journey in prurigo nodularis: what lies ahead.

Journal: Expert opinion on biological therapy
Published: April 01, 2026

Dupilumab and cutaneous T-cell lymphoma: A retrospective cohort study.

Dupilumab and cutaneous T-cell lymphoma: A retrospective cohort study.

Journal: JAAD international
Published: March 30, 2026

Real-World Experience With Dupilumab in Severe Asthma: The Spanish Multicenter Study DUPImpact.

Real-World Experience With Dupilumab in Severe Asthma: The Spanish Multicenter Study DUPImpact.

Journal: Journal of investigational allergology & clinical immunology
Published: March 30, 2026

Eosinophilic, polymorphic, and pruritic eruption associated with radiation treated with dupilumab in a patient with Hodgkin lymphoma.

Eosinophilic, polymorphic, and pruritic eruption associated with radiation treated with dupilumab in a patient with Hodgkin lymphoma.

Journal: JAAD case reports
Published: March 30, 2026

Revision endoscopic sinus surgery is rarely needed in dupilumab-treated chronic rhinosinusitis with nasal polyps.

Revision endoscopic sinus surgery is rarely needed in dupilumab-treated chronic rhinosinusitis with nasal polyps.

Journal: Rhinology
Published: March 27, 2026

Acquired Perforating Dermatoses Associated With Biologics and Janus Kinase Inhibitor Therapy: A Systematic Review.

Acquired Perforating Dermatoses Associated With Biologics and Janus Kinase Inhibitor Therapy: A Systematic Review.

Journal: Journal of cutaneous medicine and surgery
Published: March 27, 2026
Showing 1-12 of 4,857

Last Updated: 04/28/2026